Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Thursday,Benzinga reports. They currently have a $7.00 target price on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Thursday. Finally, The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.25.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $2.08 on Thursday. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The company has a fifty day moving average price of $2.46 and a two-hundred day moving average price of $2.18. The company has a market cap of $409.84 million, a PE ratio of -3.25 and a beta of 1.03.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The firm had revenue of $51.63 million during the quarter, compared to analyst estimates of $55.44 million. During the same quarter last year, the firm earned ($0.37) EPS. Equities research analysts anticipate that Esperion Therapeutics will post -0.28 earnings per share for the current year.

Institutional Trading of Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in ESPR. Foundations Investment Advisors LLC grew its holdings in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 9,872 shares during the last quarter. SJS Investment Consulting Inc. bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $55,000. SG Americas Securities LLC increased its holdings in shares of Esperion Therapeutics by 96.6% in the fourth quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company’s stock valued at $333,000 after purchasing an additional 74,433 shares in the last quarter. JPMorgan Chase & Co. raised its position in Esperion Therapeutics by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after purchasing an additional 19,588 shares during the last quarter. Finally, Eaton Financial Holdings Company LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth $73,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.